Delivery Order SPE2DB22D1017-SPE2DB25FG3WB
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zeposia 0.92 mg capsules (30-count) under a firm fixed-price contract with a ceiling value of $4,620.93. The award was made on September 15, 2025, with an ultimate completion date of October 6, 2025. This non-set-aside award represents a competitive procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,620.93 to AmerisourceBergen Drug Corp for the supply of Zeposia 0.92 mg capsules (30-count units) with a completion date of September 19, 2025. This firm fixed-price delivery order, issued on August 28, 2025, carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a competitive procurement under AmerisourceBergen's existing DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Zeposia 0.92 mg capsules (30-count units) with a contract value of $4,620.93. This non-competitive delivery order utilizes firm fixed pricing and is scheduled for completion by September 25, 2025. The award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion global pharmaceutical support...
- The Defense Logistics Agency awarded a $4,620.93 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Zeposia 0.92 mg capsules (30-count units). This non-set-aside delivery order, with an ultimate completion date of October 10, 2025, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zeposia 0.92 mg capsules (30-count units) with a ceiling value of $9,241.86. This firm fixed-price delivery order, with an ultimate completion date of August 8, 2025, represents a non-set-aside competitive award supporting federal medical procurement needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zeposia 0.92 mg capsules in a 30-count package under a firm fixed-price contract valued at $13,862.79. The award, announced on August 4, 2025, with completion targeted for August 25, 2025, represents a competitive procurement with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for Zeposia 0.92 mg capsules (30-count units) under a firm fixed-price contract valued at $13,862.79. This non-set-aside competitive award, with an ultimate completion date of August 18, 2025, will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Zeposia 0.92 mg capsules (30-count packages) under a firm fixed-price contract. The order ceiling value is $13,862.79, with an ultimate completion date of July 11, 2025. This delivery order is non-set-aside and was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the...
- The Defense Logistics Agency awarded a delivery order valued at $4,620.93 to AmerisourceBergen Drug Corp for the supply of Zeposia 0.92 mg capsules (30-count) with a firm fixed price structure. This non-set-aside award, issued on July 11, 2025, will be fulfilled at the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 1, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a $13.86K delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Zeposia 0.92 mg capsules (30-count units). This is a firm fixed price contract with no set-aside designation, scheduled for completion by September 2, 2025. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle running through December 2026 that...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG3WBDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,620.93 to AmerisourceBergen Drug Corp for the supply of Zeposia 0.92 mg capsules (30-count) on May 30, 2025, with a completion date of June 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle running through December 2026 that enables the company to supply pharmaceutical products and medical commodities to support military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company maintains an extensive portfolio of federal contract awards for brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. Zeposia, a specialty medication for neurological and immunological conditions, represents the type of specialized pharmaceutical product that the company routinely delivers through its DLA contracts, demonstrating its capability to fulfill complex federal medical supply requirements through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.6k | 5/30/25 |